Dr. Lal PathLabs Reports Q4/FY26 Results, Declares ₹4 Dividend, Acquires SDCPL

Dr. Lal PathLabs' Board approved audited financial results for Q4 and FY ended March 31, 2026. The board recommended a final dividend of INR 4/- per equity share (40%) for FY26, with June 26, 2026, as the record date. Key strategic moves include the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a wholly-owned subsidiary, and the incorporation of a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE. Additionally, the board re-appointed Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as Non-Executive Independent Director for five years. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. M/s Ernst & Young LLP and M/s A.G. Agarwal & Associates were re-appointed as Internal and Cost Auditors, respectively, for FY27. The company also allotted 82,750 equity shares under its ESOP 2022.